Ascendis Pharma
Ascendis Pharma A/S is a Danish biopharmaceutical company focused on developing therapies for rare endocrine and metabolic diseases. The company utilizes its proprietary TransCon technology platform to design prodrug therapies that provide sustained release of parent parent-drug molecules. Principal revenues are generated through product sales of its approved endocrinology treatments alongside licensing agreements and collaborative milestone payments. Its core end markets include endocrinology clinics, specialized hospitals, and rare disease treatment centers globally. Ascendis Pharma holds a strong competitive position in the global biopharmaceutical sector through its innovative long-acting therapeutic delivery platform. The company is headquartered in Hellerup, Denmark, and its American Depositary Shares are listed on the Nasdaq Global Select Market.
10 of the funds FundTelligence covers report a position in Ascendis Pharma.
- Legal name
- ASCENDIS PHARMA A/S
- Sector
- Health Care
- Country
- Denmark
- Funds holding it
- 10
Funds holding Ascendis Pharma
- Polar Capital Biotechnology Fund — Polar Capital · 4.0 % (largest positions only, October 2026)
- Artisan Global Discovery Fund — Artisan Partners · 3.0 % (largest positions only, September 2026)
- DNB Bioteknologi — DNB · 2.26 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.36 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 1.02 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 1.02 % (full portfolio disclosed, September 2026)
- SEB Läkemedelsfond — SEB · 0.75 % (full portfolio disclosed, June 2026)
- JPM Global Healthcare Fund — JPM · 0.7 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 10 funds holding it.